Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997684 | 0.81 | KCNA3 (0.37) | CHRM1KCNA3EPHX1 | |
| SCHEMBL17032849 | 0.81 | KCNA3 (0.40) | KCNA3EPHX1 | |
| SCHEMBL29252917 | 0.80 | KCNA3 (0.36) | CHRM1KCNA3EPHX1 | |
| SCHEMBL17035438 | 0.80 | KCNA3 (0.36) | CHRM1KCNA3EPHX1 | |
| SCHEMBL23064580 | 0.76 | KCNA3 (0.40) | CHRM1KCNA3EPHX1BCHE | |
| SCHEMBL28974189 | 0.76 | KCNA3 (0.40) | CHRM1KCNA3EPHX1BCHE | |
| SCHEMBL22747730 | 0.76 | CHRM1 (0.34) | CHRM1EPHX1BCHE | |
| SCHEMBL10810342 | 0.75 | EPHX1 (0.47) | CHRM1KCNA3EPHX1BCHE | |
| SCHEMBL103736 | 0.75 | — | — | |
| SCHEMBL17035439 | 0.74 | EPHX1 (0.38) | CHRM1KCNA3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110418-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20170226142-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9643986-B2 | Factor D inhibitors useful for treating inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160362399-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | CHRM1 3904/4885KCNA3 2275/4885EPHX1 168/4885 |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | CHRM1 4017/4885KCNA3 2755/4885EPHX1 1777/4885 |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | CHRM1 4620/4885KCNA3 3495/4885EPHX1 1894/4885 |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | CHRM1 4464/4885KCNA3 3818/4885EPHX1 2616/4885 |
| US-20170226142-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | CHRM1 4464/4885KCNA3 3818/4885EPHX1 2616/4885 |
| US-20160362399-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | CHRM1 4221/4885KCNA3 2029/4885EPHX1 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.